title: Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients.
abstract: Circulating fibroblast growth factor 23 (FGF23) increases renal phosphate excretion, decreases bone mineralization and is markedly increased in hemodialysis patients. Bone cells express fibroblast growth receptor 1, suggesting that FGF23 could alter bone mineralization by means of a direct effect on the skeleton and/or secondarily due to hypophosphatemia. To distinguish between these possibilities we measured serum concentrations of FGF23, parathyroid hormone, phosphate, calcium, and markers of bone remodeling, and assessed bone mineral density in 99 hemodialysis patients. FGF23 concentrations were increased in all hemodialysis patients, even in those without hyperphosphatemia, and positively correlated with serum phosphate but not with parathyroid hormone. Hemodialysis did not decrease the serum FGF23 concentration. We found no significant correlation between serum FGF23 levels and bone mineral density. Further analysis by gender or T-score did not modify these results. Serum markers of bone remodeling significantly correlated with parathyroid hormone but not with FGF23 levels. The increase in serum FGF23 concentration in hemodialysis patients cannot be solely ascribed to hyperphosphatemia. Our study suggests that the effects of FGF23 on bone mineralization are mainly due to hypophosphatemia and not a direct effect on bone.
authors.affiliation: Service de Néphrologie-Dialyse, Clinique du Landy, Saint Ouen, France.
authors.forename: P
authors.initials: P
authors.lastname: Urena Torres
authors.forename: G
authors.initials: G
authors.lastname: Friedlander
authors.forename: M C
authors.initials: MC
authors.lastname: de Vernejoul
authors.forename: C
authors.initials: C
authors.lastname: Silve
authors.forename: D
authors.initials: D
authors.lastname: Prié
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000429:Alcohol Oxidoreductases / Q000097:blood; D001842:Bone and Bones / Q000000981:diagnostic imaging; D002113:Calcification, Physiologic; D004268:DNA-Binding Proteins / Q000097:blood; D005260:Female; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000097:blood*; D006801:Humans; D054559:Hyperphosphatemia / Q000175:diagnosis; D007676:Kidney Failure, Chronic / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000097:blood*; D011859:Radiography; D006435:Renal Dialysis
chemical_list: D004268:DNA-Binding Proteins; C000717427:FGF23 protein, human; D010710:Phosphates; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23; D000429:Alcohol Oxidoreductases; C096794:C-terminal binding protein